Lexology July 12, 2024
Mintz

The Federal Trade Commission (FTC) Office of Policy Planning released an Interim Staff Report titled Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies (the Interim Report) on July 9, 2024. The Interim Report reflects the FTC’s work since it began its 6(b) study of Pharmacy Benefit Managers (PBMs) in June 2022. Our Health and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM space, including those coming from the FTC. In this Special Edition of the PBM Policy and Legislative Update, we paired up with our Antitrust colleagues to highlight the FTC’s recent activity in investigating the potential competitive consequences from conduct in the PBM industry, including Commissioner Melissa...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma, Pharma / Biotech
New 'how-to guide' for future rapid vaccine development
Infographic: R&D Spending Growth of Top Pharma Companies
Medicare prescription drug pricing variance: 5 things to know
Adoption Of Model-Informed Drug Development Can Improve Pharma ROI
Sanofi adds new $600M manufacturing plant

Share This Article